Corrigendum: Metastatic extramammary Paget's disease: Pathogenesis and novel therapeutic approach [Front Oncol, 8, (2018), (38)] doi: 10.3389/fonc.2018.00038

Keitaro Fukuda, Takeru Funakoshi

Research output: Contribution to journalComment/debate

Abstract

In the published article, there was an error in the number of ongoing clinical trial for HER2-positive unresectable or metastatic EMPD "(UMIN-000006629)". Instead of "(UMIN-000006629)", it should be "(UMIN000021311)". The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Original languageEnglish
Article number47
JournalFrontiers in Oncology
Volume8
Issue numberMAR
DOIs
Publication statusPublished - 2018 Mar 12

Fingerprint

Extramammary Paget's Disease
Clinical Trials
Therapeutics
corrigendum

Keywords

  • Anti-PD-1 antibody
  • CD163+M2 macrophage
  • CXCR4-stromal cell-derived factor-1 axis
  • HER2-PI3K/ERK signaling
  • Lymphangiogenesis
  • Metastatic extramammary Paget's disease
  • Mismatch-repair deficient
  • Receptor activator of nuclear factor kappa-B ligand-RANK signaling

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{acbdfbc798bb4192a36d3ed2b4d46696,
title = "Corrigendum: Metastatic extramammary Paget's disease: Pathogenesis and novel therapeutic approach [Front Oncol, 8, (2018), (38)] doi: 10.3389/fonc.2018.00038",
abstract = "In the published article, there was an error in the number of ongoing clinical trial for HER2-positive unresectable or metastatic EMPD {"}(UMIN-000006629){"}. Instead of {"}(UMIN-000006629){"}, it should be {"}(UMIN000021311){"}. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.",
keywords = "Anti-PD-1 antibody, CD163+M2 macrophage, CXCR4-stromal cell-derived factor-1 axis, HER2-PI3K/ERK signaling, Lymphangiogenesis, Metastatic extramammary Paget's disease, Mismatch-repair deficient, Receptor activator of nuclear factor kappa-B ligand-RANK signaling",
author = "Keitaro Fukuda and Takeru Funakoshi",
year = "2018",
month = "3",
day = "12",
doi = "10.3389/fonc.2018.00047",
language = "English",
volume = "8",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "MAR",

}

TY - JOUR

T1 - Corrigendum

T2 - Metastatic extramammary Paget's disease: Pathogenesis and novel therapeutic approach [Front Oncol, 8, (2018), (38)] doi: 10.3389/fonc.2018.00038

AU - Fukuda, Keitaro

AU - Funakoshi, Takeru

PY - 2018/3/12

Y1 - 2018/3/12

N2 - In the published article, there was an error in the number of ongoing clinical trial for HER2-positive unresectable or metastatic EMPD "(UMIN-000006629)". Instead of "(UMIN-000006629)", it should be "(UMIN000021311)". The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

AB - In the published article, there was an error in the number of ongoing clinical trial for HER2-positive unresectable or metastatic EMPD "(UMIN-000006629)". Instead of "(UMIN-000006629)", it should be "(UMIN000021311)". The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

KW - Anti-PD-1 antibody

KW - CD163+M2 macrophage

KW - CXCR4-stromal cell-derived factor-1 axis

KW - HER2-PI3K/ERK signaling

KW - Lymphangiogenesis

KW - Metastatic extramammary Paget's disease

KW - Mismatch-repair deficient

KW - Receptor activator of nuclear factor kappa-B ligand-RANK signaling

UR - http://www.scopus.com/inward/record.url?scp=85043518919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043518919&partnerID=8YFLogxK

U2 - 10.3389/fonc.2018.00047

DO - 10.3389/fonc.2018.00047

M3 - Comment/debate

AN - SCOPUS:85043518919

VL - 8

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - MAR

M1 - 47

ER -